Incidence of antiepileptic drug use in Parkinson's disease
Open Access
- 23 May 2025
- journal article
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (4) , 780-788
Abstract
Background: Antiepileptics are used to treat epilepsy but also, e.g., neuropathic pain, essential tremor and dystonia. It is not known whether they are more commonly used in persons with Parkinson's disease (PD). Objective: To assess the incidence of antiepileptic use in a nationwide cohort of persons with PD before and after the diagnosis and compared the findings to a matched cohort without PD. Methods: This register-based Finnish nationwide cohort included 18365 persons diagnosed with PD between 2001–2015. Incidence of antiepileptic initiations, from 10 years before until 10 years after the PD diagnosis, was compared to an age-, sex-, and region-matched cohort without PD. Results: Antiepileptics were more commonly initiated for persons with PD (29.3% of PD cohort and 15.2% of comparison cohort). Gabapentinoids were the most commonly initiated antiepileptics in both cohorts. A similar pattern in initiation rates was observed for both gabapentinoids and other antiepileptics, with increased incidence in the PD cohort approximately three years before the diagnosis and a significant peak around the time of PD diagnosis (the initiation rate at the time of PD diagnosis 3/100 and 1/100 person-years, for the PD and comparison cohorts, respectively). Clonazepam initiations were more common in the PD cohort (26.7% of initiations vs. 5.8% in the comparison cohort). Conclusions: The increase in antiepileptic initiation rates before the diagnosis of PD suggests that they might be used for prodromal motor or non-motor symptoms.Keywords
This publication has 28 references indexed in Scilit:
- Association Between Antiepileptic Drugs and Incident Parkinson DiseaseJAMA Neurology, 2023
- Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK PopulationJAMA Neurology, 2022
- Incidence of muscle relaxant use in relation to diagnosis of Parkinson’s diseaseInternational Journal of Clinical Pharmacy, 2020
- Risk of Developing Parkinson Disease in Bipolar DisorderJAMA Neurology, 2020
- Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. OthersJournal of the American Medical Directors Association, 2018
- Prevalence of anxiety in Parkinson's disease: A systematic review and meta‐analysisMovement Disorders, 2016
- Pharmacological Treatment of Parkinson DiseaseJAMA, 2014
- Pain in Parkinson's diseaseMovement Disorders, 2010
- Pain in Parkinson’s disease: Prevalence and characteristicsPain, 2009
- Incidence rates and treatment of neuropathic pain conditions in the general population ☆Pain, 2008